Caris Life Sciences, Inc. Common Stock (CAI) Financials

Key financial figures for Caris Life Sciences, Inc. Common Stock (Q3 2026).

Caris Life Sciences, Inc. reported revenue of $275.4 million for Q3 FY2026, up 27.0% from the same period a year earlier. Net income was $15.3 million, or $0.05 per share. Operating margin came to 7.01%, against 15.05% a year earlier. Free cash flow for the period was -$39.7 million. Across the last 5 reported quarters, quarterly revenue has risen from $216.8 million in Q3 FY2025 to $275.4 million in Q3 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Caris Life Sciences, Inc. are on the SentiSense financials page.

Revenue
$275M
Net Income
$15M
EPS
$0.05
Total Assets
$1.3B
Operating Cash Flow
-$22M

Recent quarters

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
Q3 FY2026$275M$15M$0.057.01%-$40M
Q2 FY2026$264M-$637K-$0.0010.21%$29M
Q1 FY2026$216M-$510K-$0.002.44%$23M
Q4 FY2025$293M$82M$0.2930.19%$40M
Q3 FY2025$217M$24M$0.0815.05%$55M

Recent fiscal years

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
FY2025$812M-$538M-$1.905.56%$67M
FY2024$412M-$282M-$1.35-62.37%-$254M
FY2023$306M-$341M-$1.82-104.38%-$298M

Frequently asked questions

What was Caris Life Sciences, Inc.'s revenue last quarter?

Caris Life Sciences, Inc. reported revenue of $275.4 million for Q3 FY2026, up 27.0% from the same period a year earlier.

Is Caris Life Sciences, Inc. profitable?

Yes. Caris Life Sciences, Inc. reported net income of $15.3 million for Q3 FY2026, a net margin of 5.54% on revenue.

How has Caris Life Sciences, Inc.'s margin trended?

Operating margin was 7.01% in Q3 FY2026, compared with 15.05% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.

How much free cash flow did Caris Life Sciences, Inc. generate?

Caris Life Sciences, Inc. generated free cash flow of -$39.7 million in Q3 FY2026, after capital expenditure.

Full income statement, balance sheet and cash flow for Caris Life Sciences, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.